FoxO1对肝脏脂代谢的影响

FoxO1 is a member of the FoxO family of transcription factor and is known of it's important role in insulin action. More and more studies have shown that FoxO1 also plays an important role in liver lipid metabolism. The mechanism may be that Foxo1 up-regulated microsomal triglyceride transfer protein (MTP) and Apolipoprotein B(Apo B) expression, promoting the synthesis of VLDL; and also promoting the expression of Apolipoprotein CⅢ(Apo CⅢ), inhibition the activity of lipoprotein lipase (LPL), thereby reducing triglyceride decomposition; FoxO1 can also inhibit SREBP-1c expression, inhibit fat synthesis. In conclusion, enhanced FoxO1 activity can cause excessive circulating VLDL and TG, which can lead to the occurrence of metabolic syndrome. Specific inhibition of the activity of FoxO1 in liver can reduce the production of VLDL-TG and improve glucose and lipid metabolism. Therefore, the research and development of targeted inhibition of FoxO1 activity in vivo may have important therapeutic value and clinical significance for the clinical treatment of dyslipidemia.